David A. Karnofsky

TL;DR: Daunomycin is temporarily effective in some cases of neuroblastoma, reticulum cell sarcoma and rhabdomyosarcoma, and in patients receiving maintenance doses of dauncycin the development of tachypnea, tachycardia pulmonary insufficiency, heart failure and hypotension possibly is associated with daunomcin but the evidence is unclear.

TL;DR: A new antimetabolite, 6-mercaptopurine, has been shown to produce good clinical and hematologic remissions in fifteen out of forty-five children with acute leukemia, and this compound would appear to be of fundamental as well as practical interest.

TL;DR: During therapeutic trials with E. coli L‐asparaginase in 131 children and 143 adults with neoplastic disease the following signs of toxicity have been observed: fever, nausea and vomiting, weight loss, somnolence, lethargy, confusion, hypolipidemia, hyperlipidemia and hypoproteinemia.

TL;DR: Of the 73 adequately treated ALL patients, the overall remission rate was 62%; the median duration of remission was 60 days with a range of 15 to 248 days; the duration of relapse appeared to be independent of dose.

TL;DR: Hydroxyurea-induced inhibition of thymidine incorporation by monolayers of HeLa cells was partially prevented and reversed by addition of deoxyadenosine, deoxyguanosine, and deoxycytidine to the culture medium, compatible with the postulate that this compound inhibits reduction of ribonucleotides to deoxyribon nucleotides.